Skip to main content
. 2020 Dec 23;73(3):e629–e637. doi: 10.1093/cid/ciaa1879

Figure 1.

Figure 1.

Chlamydia trachomatis seroprevalence among US females aged 18 to 39 years. A, Concordance and discordance of 2 anti-C. trachomatis Pgp3 IgG assays among females age 18–39 (n = 697). MBA positivity is represented in yellow, ELISA positivity represented in blue and concordance of MBA and ELISA in green. B, Anti-C. trachomatis Pgp3 IgG positivity among females with current chlamydia detection by urine NAAT test (n = 42) and without chlamydia detection (n = 1683). C, Anti-C. trachomatis Pgp3 IgG positivity among females diagnosed with chlamydia in the past 12 months (n = 33) and those not diagnosed (n = 1391). D, anti-C. trachomatis Pgp3 IgG positivity among females ever treated for PID or pelvic infection (n = 61) and those not diagnosed (n = 1471). Note: Data are unweighted. 95% confidence intervals are exact binomial confidence intervals. Definitions of positivity: ELISA, positive on the anti-pgp3 ELISA; MBA, positive on the anti-pgp3 MBA; Both, positive on both an anti-pgp3 MBA and ELISA; Either, positive on either the anti-pgp3 MBA and ELISA. Abbreviations: IgG, immunoglobin G; ELISA, enzyme-linked immunosorbent assay; MBA, multiplex bead format assay; NAAT, nucleic acid amplification test; Pgp3, plasmid gene product 3; PID, pelvic inflammatory disease.